Abstract
Muscarinic receptor antagonists form the mainstay of the therapeutic options for airway, bladder, and gastrointestinal smooth muscle disorders. Both M2 and M3 muscarinic receptors are involved in mediating smooth muscle contractility, although the relative functional contribution of each subtype, especially in the disease state, is unclear. Because the potency and selectivity of compounds for a given receptor in an in vivo setting can be dissimilar to that observed in an in vitro system, we developed an in vivo assay to simultaneously determine the absolute potency and selectivity of muscarinic receptor antagonists at M2 and M3 receptors using the pithed rat. Methacholine (MCh)-induced bradycardia and depressor responses were used as surrogate functional endpoints for M2 and M3 receptor activation, respectively. The influence of the muscarinic antagonists, tolterodine, oxybutynin, darifenacin, Ro 320-6206, solifenacin, or tiotropium on the MCh-induced responses were studied. The estimated DR10 values (dose producing a tenfold shift in the MCh curve) of tolterodine, oxybutynin, darifenacin, Ro 320-6206, solifenacin, and tiotropium for the M2 muscarinic receptor-mediated bradycardia were 0.22, 1.18, ∼2.6, 0.025, 0.40, and 0.0026 mg/kg, respectively, and 0.14, 0.18, 0.11, 3.0, 0.18, and 0.0017 mg/kg, respectively, for the M3 muscarinic receptor-mediated depressor response. In a separate set of experiments, a single intravenous dose of tiotropium was administered before a MCh curve at 1, 3, 6, or 9 h to determine if tiotropium exhibited time-dependent selectivity for the M3 receptor as has been reported from in vitro studies. The results indicate a slight preference of tiotropium for the M3 receptor at later time points. The pithed rat assay may serve useful for elucidating the functional contribution of M2 and M3 receptors to the in vivo pharmacological effects of antagonists in disease animal models.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams P (2001) Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother 2:1685–1701
Alabaster VA (1997) Discovery & development of selective M3 antagonists for clinical use. Life Sci 60:1053–1060
Alabaster VA (2002) The fall and rise of in vivo pharmacology. Trends Pharmacol Sci 23:13–18
Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319–323
Angeli P, Cantalamessa F, Gulini U, Melchiorre C (1995) Selective blockade of muscarinic M2 receptors in vivo by the new antagonist tripitramine. Naunyn Schmiedeberg’s Arch Pharmacol 352:304–307
Barnes PJ (2000) The pharmacological properties of tiotropium. Chest 117:63S–66S
Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O’Connor B (1995) Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 56:853–859
Callahan MJ (2002) Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 35:S58–S67
Caulfield MP, Birdsall NJM (1998) International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279–290
Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:33–46
Disse B (2001) Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci 68:2557–2564
Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52:537–544
Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de JA, van Zwieten PA (1987) Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 242:257–262
Eglen RM, Hegde SS, Watson N (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48:531–565
Eglen RM, Choppin A, Dillon MP, Hegde S (1999) Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol 3:426–432
Ehlert FJ (2003a) Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle. Life Sci 74:355–366
Ehlert FJ (2003b) Pharmacological analysis of the contractile role of M2 and M3 muscarinic receptors in smooth muscle. Receptors Channels 9:261–277
Ehlert FJ, Ostrom RS, Sawyer GW (1997) Subtypes of the muscarinic receptor in smooth muscle. Life Sci 61:1729–1740
Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348
Gross NJ (1988) Ipratropium bromide. N Engl J Med 319:486–494
Hansel TT, Barnes PJ (2002) Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc) 38:585–600
Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80–S87
Hegde SS, Chopin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM (1997) Functional Role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120:1409–1418
Hegde SS, Mammen M, Jasper JR (2004) Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies. Curr Opin Invest Drugs 5(1):40–49
Hosey MM (1992) Diversity of structure, signaling and regulation within the family of muscarinic cholinergic receptors. FASEB J 6:845–852
Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K (2002) M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg’s Arch Pharmacol 366:97–103
Jaiswal N, Lambrecht G, Mutschler E, Tacke R, Malik KU (1991) Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther 258:842–50
Schneider T, Hein P, Michel-Reher MB, Michel MC (2005) Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedeberg’s Arch Pharmacol 372:71–78
Timmermans PB, Van Zwieten PA (1980) Postsynaptic alpha 1- and alpha 2-adrenoceptors in the circulatory system of the pithed rat: selective stimulation of the alpha 2-type by B-HT 933. Eur J Pharmacol 63(2–3):199–202
van Charldorp KJ, de JA, Thoolen MJ, van Zwieten PA (1985) Subclassification of muscarinic receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat. Selectivity of some classical agonists. Naunyn Schmiedeberg’s Arch Pharmacol 331:301–306
Wallis RM, Napier CM (1999) Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 64:395–401
Wess J, Angeli P, Melchiorre C, Moser U, Mutschler E, Lambrecht G (1988) Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedeberg’s Arch Pharmacol 338:246–249
Yamada M (2002) The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist. J Pharmacol Exp Ther 300:681–687
Zhao S-H, Berger J, Miller AK, Flippin LA, Clark RD, Maag H, Stepan G, Watson N, Shetty SG, Cefalu JS, Dawson MW, Rocha C (2001) Novel 2-benzyl-piperidine derivatives as selective M2 muscarinic receptor antagonists. Am Chem Soc Proc 221:ORGN–597
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Armstrong, S.R., Briones, S., Horger, B. et al. Pharmacological analysis of the interaction of antimuscarinic drugs at M2 and M3 muscarinic receptors in vivo using the pithed rat assay. Naunyn-Schmied Arch Pharmacol 376, 341–349 (2008). https://doi.org/10.1007/s00210-007-0224-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-007-0224-0